

Supplementary Table 1. The list of the primer sequences used as PCR and qRT-PCR.

	Primer	Forward primer	Reverse primer
PCR	Mouse <i>Gapdh</i>	5'-TTAGCCCCCTGGCCAAGG-3'	5'-CTTACTCCTTGGAGGCCATG-3'
	Mouse <i>G-CSF</i>	5'-GTTGGCAACATCCAGCTGAAGCAA-3'	5'-TTCCTGCTTAAGTCCCTGGAGCAA-3'
	mouse <i>Ep2</i>	5'-CAGGAGAGGAGAGAGGACTT-3'	5'-GAAGTCCGACAACAGAGGAC-3'
	mouse <i>Ep4</i>	5'-GTTGGTGGATGAGGTTAGTG -3'	5'-CTAGTGGGAGTCCAGATGAA -3'
	human β -actin	5'-CGTGACATTAAGGAGAAGCTGTG-3'	5'-GCTCAGGAGGAGCAATGATCTTGA-3'
	human G-CSF	5'-TGAGTGTGCCACCTACAAGC-3'	5'-GACACCTCCAGGAAGCTCTG-3'
	human EP2	5'-TTCATCCGGCACGGGCGGACCGC-3'	5'-GTCAGCCTGTTTACTGGCATCTG-3'
	human EP4	5'-CCTCCTGAGAAAGACAGTGCT-3'	5'-AAGACACTCTCTGAGTCCT-3'
qRT-PCR	human GAPDH	5'-CATGAGAAGTATGACAACAGCCT-3'	5'-AGTCCTTCCACGATACCAAAGT-3'
	human PD-L1	5'-TCAATGCCCATACAACAAA-3'	5'-GCTTGTCCAGATGACTTCG-3'

Supplementary Table 2. Antibodies list of immunofluorescence staining.

Figure No.	Primary antibodies			Secondary antibodies			Detection		
	Antibodies	Manufacturer (Cat#)	Condition	Antibodies	Manufacturer (Cat#)	Condition	Antibodies	Manufacturer (Cat#)	Condition
Figure 5c	Anti-mouse ALDH1A1	Abcam (#ab52492)	1:100, 4°C Over night	Histofine Simple Stain Max-PO	Nichirei Bioscience (#424144)	RT 30min	TSA Cyanine3 System	PerkinElmer (#SAT704A001EA)	RT 10min
	Anti-mouse PD-L1	Proteintech (#66248-1-Ig)	1:2000, 4°C Over night	Anti-mouse AlexaFluor 488	Abcam (#ab150105)	RT 120min	-	-	-
Figure 5d	Anti-mouse Gr-1	R&D systems (# MAB1037)	1:200, 4°C Over night	Biotinylated IgG	Anti-rat Vector (#BA4000)	RT 30min RT 10min	TSA Fluorescein System	PerkinElmer (#SAT701001EA)	RT 10min
	Anti-mouse ALDH1A1	Abcam (#ab52492)	1:100, 4°C Over night	Histofine Simple Stain Max-PO	Nichirei Bioscience (#424144)	RT 30min	TSA Cyanine3 System	PerkinElmer (#SAT704A001EA)	RT 10min

RT; Room temperature

Supplementary Table 3. Clinicopathological characteristics of the patients with or without leukocytosis.

		All patients (N=340)	WBC \geq 10000/ μ l (n=24)	WBC <10000/ μ l (n=316)	
		n (%)	n (%)	n (%)	P-value
Age (years)	<50	112 (32.6)	12 (50.0)	100 (31.7)	0.0651
	\geq 51	232 (67.4)	12 (50.0)	216 (68.4)	
FIGO stage	I- II	188 (55.3)	12 (50.)	176 (55.7)	0.5884
	III- IV	152 (44.7)	12 (50.0)	140 (44.3)	
Histology	Serous	131 (38.5)	7 (29.2)	124 (39.2)	0.0511
	Clear	82 (24.1)	2 (8.3)	80 (25.3)	
	Endometrioid	60 (17.7)	6 (25.0)	54 (17.1)	
	Mucinous	31 (9.1)	3 (12.5)	28 (8.9)	
	Others	36 (10.6)	6 (25.0)	30 (9.5)	
LN metastasis	Negative	250 (73.5)	18 (75.0)	232 (73.4)	0.8655
	Positive	90 (26.5)	6 (25.0)	84 (26.6)	
Peritoneal washing ¹	Negative	147 (44.4)	11 (45.8)	136 (44.3)	0.8842
	Positive	184 (55.6)	13 (54.2)	171 (55.7)	
Optimal surgery ²	Yes	264 (80.5)	14 (70.0)	250 (81.2)	0.2220
	No	64 (19.5)	6 (30.0)	58 (18.8)	
CA125 (U/ml)	<500	216 (63.5)	11 (45.8)	205 (64.9)	0.0617
	\geq 500	124 (36.5)	13 (54.2)	111 (35.1)	

WBC; white blood cell, FIGO; The International Federation of Gynecology and Obstetrics, LN; lymphocyte node, CA125; carbohydrate antigen 125

¹ Peritoneal washing was not indicated for 9 cases.

² Surgery was performed in 328 cases.